Related Experiment Video

Updated: Apr 18, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Structural investigation of B-Raf paradox breaker and inducer inhibitors

Rohit Arora1, Michela Di Michele, Elisabeth Stes

  • 1Institut de Chimie Organique et Analytique, UMR CNRS-Université d'Orléans 7311 , Université d'Orléans BP 6759, Orléans 45067 Cedex 2, France.

Journal of Medicinal Chemistry
|January 23, 2015
PubMed

Insights

New B-Raf inhibitors, termed paradox breakers, selectively target the V600E mutation. They avoid paradoxical MAPK pathway hyperactivation seen with traditional inhibitors, offering a safer therapeutic approach for cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The B-Raf V600E mutation drives uncontrolled cell proliferation and tumorigenesis via aberrant MAPK pathway signaling.
  • ATP-competitive B-Raf inhibitors can paradoxically hyperactivate the MAPK pathway in wild-type B-Raf cells through conformational changes and C-Raf heterodimerization.

Purpose of the Study:

  • To investigate the structural and conformational effects of novel 'paradox breaker' inhibitors on the B-Raf kinase domain.
  • To understand the molecular mechanisms differentiating paradox breakers from traditional inducers.
  • To provide insights for designing improved B-Raf inhibitors with enhanced selectivity and reduced off-target effects.

Main Methods:

  • Structural analysis of B-Raf kinase domain complexes.
  • Conformational studies using biophysical techniques.
  • Cellular assays to assess pathway modulation.

Main Results:

  • Subtle structural differences between paradox inducers and breakers result in distinct conformational states when bound to B-Raf.
  • Paradox breakers inhibit B-Raf(V600E) activity without inducing MAPK pathway hyperactivation in wild-type B-Raf.
  • These findings elucidate the activation mechanism of B-Raf by ATP-competitive inhibitors.

Conclusions:

  • Paradox breakers represent a promising new class of inhibitors for B-Raf-mutant cancers.
  • Understanding B-Raf conformational dynamics is crucial for developing selective and effective cancer therapeutics.
  • This research aids in the rational design of next-generation B-Raf inhibitors lacking agonistic activity.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.4K